Novavax (NVAX) Short Interest Ratio & Short Volume

Short interest is the volume of Novavax shares that have been sold short but have not yet been covered or closed out. As of May 15th, investors have sold 45,290,000 shares of NVAX short. Learn More on Novavax's current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. NVAX shares currently have a short interest ratio of 4.0. Learn More on Novavax's short interest ratio.

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Novavax: Walleye Trading LLC, Ikarian Capital LLC, SG Americas Securities LLC, Capstone Investment Advisors LLC, BNP Paribas Financial Markets, and IMC Chicago LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

Novavax saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 45,290,000 shares, an increase of 0.8% from the previous total of 44,930,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Here is how the short interest of companies in the sector of "medical" compare to Novavax: Twist Bioscience Co. (18.38%), Denali Therapeutics Inc. (8.09%), Iovance Biotherapeutics, Inc. (22.90%), Relay Therapeutics, Inc. (8.96%), Adaptive Biotechnologies Co. (8.92%), Kodiak Sciences Inc. (3.76%), CRISPR Therapeutics AG (18.05%), Exelixis, Inc. (3.77%), Halozyme Therapeutics, Inc. (6.80%), Ionis Pharmaceuticals, Inc. (6.43%),

As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.81 billion), Charter Communications, Inc. ($3.30 billion), Occidental Petroleum Co. ($3.10 billion), General Motors ($2.84 billion), Moderna, Inc. ($2.77 billion), AppLovin Co. ($2.22 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.16 billion), Tractor Supply ($2.12 billion), and Williams-Sonoma, Inc. ($2.12 billion). View all of the most shorted stocks.

Short selling NVAX is an investing strategy that aims to generate trading profit from Novavax as its price is falling. NVAX shares are trading down $0.22 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Novavax occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of NVAX, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including NVAX, twice per month. The most recent reporting period available is May, 15 2024.